Rigel Pharmaceuticals, Inc.RIGLNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +60.92% | +80.58% | +176.01% | +25.59% | +21.19% |
| Gross Profit Growth | +61.89% | +77.85% | +185.54% | +36.86% | +23.24% |
| EBITDA Growth | +505.41% | +0.00% | +3774.88% | +99.56% | +19.98% |
| Operating Income Growth | +747.15% | +0.00% | +13569.57% | +102.19% | +39.12% |
| Net Income Growth | +1845.86% | +0.00% | +0.00% | +124.62% | +1769.22% |
| EPS Growth | +1814.89% | +0.00% | +0.00% | +118.31% | +1737.04% |
| EPS Diluted Growth | +1795.73% | +0.00% | +0.00% | +108.57% | +1663.75% |
| Weighted Average Shares Growth | +1.15% | +1.64% | +1.91% | +2.49% | +1.93% |
| Weighted Average Shares Diluted Growth | +3.09% | +3.70% | +3.49% | +8.54% | +4.75% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +10011.59% | +10.85% | +51.55% |
| Free Cash Flow Growth | +0.00% | +0.00% | +38071.25% | +10.84% | +51.91% |
| Receivables Growth | +36.22% | +51.01% | +38.07% | +50.20% | +24.39% |
| Inventory Growth | +8.69% | -29.18% | +29.33% | +330.83% | +91.70% |
| Asset Growth | +39.88% | +39.09% | +61.00% | +73.96% | +213.21% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +11581.27% |
| Debt Growth | -1.01% | +0.94% | +1.18% | +1.08% | -11.11% |
| R&D Expense Growth | +76.77% | +39.99% | +23.12% | +18.94% | +89.72% |
| SG&A Expenses Growth | +9.94% | -2.58% | +4.31% | +7.00% | +1.60% |